{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:25:37Z","timestamp":1774657537478,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina de Familia. SEMERGEN"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.semerg.2022.04.005","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T08:37:17Z","timestamp":1653035837000},"page":"403-410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effects of treatment with monacolin K, berberine and coenzyme Q10 on lipid metabolism in patients with moderate cardiovascular risk"],"prefix":"10.1016","volume":"48","author":[{"given":"F.","family":"Martinez-Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Corbella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Sarasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Trias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Petitb\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Licer\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.M.","family":"S\u00e1nchez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Arn\u00e1s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"de Dios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Florido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Pint\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semerg.2022.04.005_bib0155","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semerg.2022.04.005_bib0160","first-page":"140","article-title":"ESC Scientific Document Group 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","author":"Mach","year":"2019","journal-title":"Eur Heart J Atherosc"},{"key":"10.1016\/j.semerg.2022.04.005_bib0165","article-title":"Da Vinci study EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the Da Vinci study","volume":"zwaa047","author":"Ray","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.semerg.2022.04.005_bib0170","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semerg.2020.08.007","article-title":"Manejo del paciente con dislipidemia en Espa\u00f1a. Proyecto Cardio Right Care Control del Riesgo Cardiovascular","volume":"47","author":"Barrios","year":"2021","journal-title":"Semergen"},{"key":"10.1016\/j.semerg.2022.04.005_bib0175","first-page":"218","article-title":"Decalogue of the Spanish Society of Arteriosclerosis to reduce therapeutic inertia","volume":"29","author":"Blasco","year":"2017","journal-title":"Clin Investig Arteriosc"},{"key":"10.1016\/j.semerg.2022.04.005_bib0180","first-page":"S35","article-title":"Diagnosis prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group Update (2016)","volume":"32","author":"Mancini","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.semerg.2022.04.005_bib0185","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.ejim.2014.06.008","article-title":"Nutraceuticals for the treatment ofhypercholesterolemia","volume":"25","author":"Mannarino","year":"2014","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.semerg.2022.04.005_bib0190","article-title":"Est\u00e1ndares SEA 2022 para el control global del riesgo cardiovascular","author":"Mostaza","year":"2022","journal-title":"Clin Investig Arteriosc"},{"issue":"Suppl. 1","key":"10.1016\/j.semerg.2022.04.005_bib0195","first-page":"1","article-title":"en nombre de la Sociedad Espa\u00f1ola de Arteriosclerosis; Miembros de la Sociedad Espa\u00f1ola de Arteriosclerosis. Standards for global cardiovascular risk management arteriosclerosis","volume":"31","author":"Mostaza","year":"2019","journal-title":"Clin Investig Arteriosc"},{"key":"10.1016\/j.semerg.2022.04.005_bib0200","doi-asserted-by":"crossref","first-page":"192","DOI":"10.14797\/mdcj-15-3-192","article-title":"Red yeast rice for hypercholesterolemia","volume":"15","author":"Cicero","year":"2019","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"10.1016\/j.semerg.2022.04.005_bib0205","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.bbrc.2007.08.060","article-title":"Berberine-induced LDLR upregulation involves JNK pathway","volume":"362","author":"Lee","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.semerg.2022.04.005_bib0210","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/acm.2013.0088","article-title":"Alkaloids as aldose reductase inhibitors, with special reference to berberine","volume":"20","author":"Gupta","year":"2014","journal-title":"J Altern Complement Med"},{"key":"10.1016\/j.semerg.2022.04.005_bib0215","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.phrs.2017.03.023","article-title":"Regulation of PCSK9 by nutraceuticals","volume":"120","author":"Momtazi","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.semerg.2022.04.005_bib0220","doi-asserted-by":"crossref","first-page":"e009835","DOI":"10.1161\/JAHA.118.009835","article-title":"Effects of coenzyme Q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials","volume":"7","author":"Qu","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.semerg.2022.04.005_bib0225","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.3390\/nu13093128","article-title":"Nutraceutical combinations in hypercholesterolemia: evidence from randomised, placebo-controlled clinical trials","volume":"13","author":"Protic","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.semerg.2022.04.005_bib0230","unstructured":"American College of Cardiology. ASCVD risk stimator plus. Available from: http:\/\/tools.acc.org\/ASCVD-Risk-Estimator-Plus\/#!\/calculate\/estimate\/ [Consulted 21 Jan 2021]."},{"key":"10.1016\/j.semerg.2022.04.005_bib0235","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1056\/NEJMoa1800389","article-title":"for the PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts","volume":"378","author":"Estruch","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2022.04.005_bib0240","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","article-title":"Apolipoprotein B particles and cardiovascular disease: a narrative review","volume":"4","author":"Sniderman","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.semerg.2022.04.005_bib0245","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jacc.2018.04.040","article-title":"International lipid expert panel (ILEP) the role of nutraceuticals in statin intolerant patients","volume":"72","author":"Banach","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semerg.2022.04.005_bib0250","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.phrs.2016.01.030","article-title":"Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: a systematic review and meta-analysis","volume":"105","author":"Sahebkar","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.semerg.2022.04.005_bib0255","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.numecd.2009.05.017","article-title":"Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study","volume":"20","author":"Affuso","year":"2010","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.semerg.2022.04.005_bib0260","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.201700280","article-title":"Efficacy and safety of sugarcane policosanol on dyslipidemia: a meta-analysis of randomized controlled trials","volume":"62","author":"Gong","year":"2018","journal-title":"Mol Nutr Food Res"},{"issue":"Suppl. 2","key":"10.1016\/j.semerg.2022.04.005_bib0265","first-page":"28","article-title":"Non-HDL cholesterol as a therapeutic goal","volume":"31","author":"Brea","year":"2019","journal-title":"Clin Investig Arteriosc"},{"key":"10.1016\/j.semerg.2022.04.005_bib0270","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/MED.0000000000000624","article-title":"Expert position statements: comparison of recommendations for the care of adults and youth with elevated lipoprotein(a)","volume":"28","author":"Wilson","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.semerg.2022.04.005_bib0275","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.amjcard.2008.02.056","article-title":"Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction","volume":"101","author":"Lu","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.semerg.2022.04.005_bib0280","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.semerg.2022.04.005_bib0285","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/bcp.13171","article-title":"Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system","volume":"83","author":"Mazzanti","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.semerg.2022.04.005_bib0290","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jpba.2014.07.039","article-title":"Chemical profiling and quantification of monacolins and citrinin in red yeast rice commercial raw materials and dietary supplements using liquid chromatography-accurate QToF mass spectrometry: chemometrics application","volume":"100","author":"Avula","year":"2014","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.semerg.2022.04.005_bib0295","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jep.2014.09.049","article-title":"Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension","volume":"161","author":"Lan","year":"2015","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.semerg.2022.04.005_bib0300","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.12654","article-title":"Effects of statins on mitochondrial pathways","author":"Mollazadeh","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"}],"container-title":["Medicina de Familia. SEMERGEN"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S113835932200106X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S113835932200106X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:41:54Z","timestamp":1761108114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S113835932200106X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S113835932200106X"],"URL":"https:\/\/doi.org\/10.1016\/j.semerg.2022.04.005","relation":{},"ISSN":["1138-3593"],"issn-type":[{"value":"1138-3593","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of treatment with monacolin K, berberine and coenzyme Q10 on lipid metabolism in patients with moderate cardiovascular risk","name":"articletitle","label":"Article Title"},{"value":"Medicina de Familia. SEMERGEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semerg.2022.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Sociedad Espa\u00f1ola de M\u00e9dicos de Atenci\u00f3n Primaria (SEMERGEN). Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}